Victoza
Oct 10, 2017
Novo petitions FDA;J&J invests; Xarelto’s trial; Roche’s Tecentriq
Novo petitions FDA to require copies of Victoza to conduct clinical trials With one drugmaker already trying to pry patent protection off of Novo Nordisk’s blockbuster Victoza before its 2022 expiration, the insulin specialist has taken new steps to deter copies. The Danish drugmaker has filed a citizen petition arg...
Read More...
-Agonist.png "Toll-like Receptors Agonist")
